Prophylactic lateral pelvic lymph node dissection in stage IV low rectal cancer

Table 1 Clinicopathological characteristics of the 50 patients

Variable
Age (yr)1	58.5 (31-78)
Sex
Male:female	43:7
Preoperative CEA level (ng/mL)1	24.5 (1.6–6856.5)
Tumor size (mm)1	63.0 (22–130)
T category
T2:T3:T4	2:31:17
Histopathological grading
G1:G2:G3	1:35:14
Lymphatic invasion
Absence:Presence	6:44
Venous invasion
Absence:Presence	10:40
Lymph node metastasis
Absence:Presence	9:41
Pathological LPLN metastasis
Absence:Presence	15:12
No. of metastatic organs
1:2:3	44:5:1
Metastatic organ
Liver:Lung:Peritoneum:Paraaortic LN:Bone	28:16:10:1:2
Grade of liver metastasis2
H1:H2:H3	14:5:9
Grade of lung metastasis2
LM1:LM2:LM3	8:7:1
Grade of peritoneal metastasis2
P1:P2:P3	8:1:1
Grade ≥ 3 Complication of primary tumor resection
Absence:Presence	38:12
Residual tumor status
R0:R2	20:30
Preoperative chemotherapy
Absence:Presence	41:9
Postoperative chemotherapy
Absence:Presence	7:43
Chemotherapy regimen
5FU-LV and/or S-1 and/or capecitabine	25
FOLFOX and/or CapeOX and/or FOLFIRI	33
Bevacizumab	18
Cetuximab or panitumumab	4

¹Data are expressed as median (range);

²Distant metastasis was classified according to the Japanese Society for Cancer of the Colon and Rectum classification (See material and method). FOLFOX oxaliplatin, leucovorin, and 5FU, CapeOX oxaliplatin and capecitabine, FOLFIRI irinotecan, leucovorin, and 5FU. CEA: Carcinoembryonic antigen; LPLN: Lateral pelvic lymph node; LN: Lymph node; TME: Total mesorectal excision; 5FU: 5-Fluorouracil; LV: Leucovorin.